Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHymowitz, Sarah G.en
dc.contributor.authorJin, Shaen
dc.contributor.authorKhaw, Seong Linen
dc.contributor.authorKovar, Peter J.en
dc.contributor.authorLam, Lloyd T.en
dc.contributor.authorLee, Jackieen
dc.contributor.authorMaecker, Heather L.en
dc.contributor.authorMarsh, Kennan C.en
dc.contributor.authorMason, Kylie D.en
dc.contributor.authorMitten, Michael J.en
dc.contributor.authorSampath, Deepaken
dc.contributor.authorNimmer, Paul M.en
dc.contributor.authorOleksijew, Anatolen
dc.contributor.authorPark, Chang H.en
dc.contributor.authorPark, Cheol-Minen
dc.contributor.authorPhillips, Darren C.en
dc.contributor.authorRoberts, Andrew W.en
dc.contributor.authorSeymour, John F.en
dc.contributor.authorSmith, Morey L.en
dc.contributor.authorSullivan, Gerard M.en
dc.contributor.authorTahir, Stephen K.en
dc.contributor.authorWendt, Michael D.en
dc.contributor.authorXiao, Yuen
dc.contributor.authorXue, John C.en
dc.contributor.authorZhang, Haichaoen
dc.contributor.authorHumerickhouse, Rod A.en
dc.contributor.authorRosenberg, Saul H.en
dc.contributor.authorElmore, Steven W.en
dc.contributor.authorTse, Chrisen
dc.contributor.authorSouers, Andrew J.en
dc.contributor.authorLeverson, Joel D.en
dc.contributor.authorBoghaert, Erwin R.en
dc.contributor.authorAckler, Scott L.en
dc.contributor.authorCatron, Nathaniel D.en
dc.contributor.authorChen, Junen
dc.contributor.authorDayton, Brian D.en
dc.contributor.authorDing, Hongen
dc.contributor.authorEnschede, Sari H.en
dc.contributor.authorFairbrother, Wayne J.en
dc.contributor.authorHuang, David C. S.en
dc.identifier.citationSouers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., et al. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature medicine, 19(2), 202-208.en
dc.description.abstractProteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2–like 1 (BCL-XL), which has shown clinical efficacy in some BCL-2–dependent hematological cancers. However, concomitant on-target thrombocytopenia caused by BCL-XL inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199. This compound inhibits the growth of BCL-2–dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2–dependent hematological cancers.en
dc.relation.ispartofseriesNature medicineen
dc.titleABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsen
dc.typeJournal Articleen
dc.contributor.schoolSchool of Physical and Mathematical Sciencesen
item.fulltextNo Fulltext-
Appears in Collections:SPMS Journal Articles

Citations 1

Updated on Dec 28, 2021

Citations 1

Updated on Mar 6, 2021

Page view(s) 10

Updated on Jan 17, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.